All articles by Phillip Broadwith – Page 24
-
Business
1050 jobs shed in Sabic restructuring
Cuts will be spread across European operations, but the Netherlands and UK take the brunt
-
Business
Objections raised to GSK pay-for-delay deals
The UK Office of Fair Trading believes deals to delay generic drugs infringed competition laws
-
BusinessDeadly blast destroys US fertiliser plant
Up to 15 dead and over 160 injured in a fire and explosion in Waco, Texas
-
News
Biofuels are expensive and unsustainable, report says
UK think tank Chatham House criticises EU fuel policy
-
Research
Polymer lubricant may stave off knee surgery
Development of new synthesis method for high molecular weight polymer, which could be used to lubricate joints
-
Business
Waitrose bans neonicotinoid pesticides
Supermarket introduces precautionary ban on fresh produce suppliers using neonicotinoids until their effect on bees is clarified
-
Business
BASF introduces cell-based allergen test
Non-animal test for cosmetic ingredients to comply with Reach regulation
-
Business
Veolia and Total open oil recycling plant
Osilub plant will re-refine used oils into high grade engine lubricants
-
FeatureFrom molecules to medicines
Turning an active drug molecule into a finished product requires as much chemistry as developing the drug in the first place, as Phillip Broadwith discovers
-
Business
Morning sickness drug reintroduced to US
After being withdrawn due to litigation, the drug has been approved by the FDA
-
Business
European project to boost industry energy efficiency
Initiative will focus on smaller companies and provide tools to assess and reduce energy use
-
Business
Roche to release Tamiflu trial data
The company will drip feed data to the Cochrane Collaboration, but with some elements redacted
-
Research
A solution to fluoronium riddle
Elegant experiment lets chemists glimpse the elusive ion by tallying isomers
-
Business
Amylin headquarters to close with further job losses
Bristol-Myers Squibb plans to shutter the San Diego, US, site following last year’s merger
-
News
Regeneron expands, creating 400 new jobs
US biotech firm announces second expansion in six months
-
Research
New antimalarial drug class resists resistance
Drug candidate looks promising as scientists draw on past failures to address toxicity problems
-
Business
AstraZeneca partners with Moderna for $240 million
Pharma company sheds more jobs and backs messenger RNA therapeutics
-
-
NewsScience community urged to unite on open access
While many sticking points remain, these should not be allowed to derail changes to the publication of research in the UK, meeting told
-
NewsFunding council backs doctoral training centres with £350m
Money will fund new centres and some existing ones, while others may slowly fade away